Having closed a nine-figure fundraising round, a newly launched biotechnology company hopes to rewire the immune system with drugs aimed at a special kind of nerve cell. Nilo Therapeutics debuted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback